Lamitrin S

Lamotrigine, the active ingredient in Lamitrin S, is an anticonvulsant presented as an oral formulation for oral use. It is employed to manage seizure disorders and to stabilize mood in bipolar disorder, and is prescribed for adult and pediatric patients as appropriate.

GNH USA supplies Lamitrin S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Lamotrigine is an anticonvulsant that modulates neuronal excitability in seizure disorders and provides mood stabilization in psychiatric conditions.

- Epilepsy: reduces the frequency and severity of both partial (focal) seizures and generalized tonic‑clonic seizures, improving overall seizure control. - Bipolar disorder (maintenance therapy): helps prevent recurrence of depressive, manic, and mixed episodes, contributing to long‑term mood stability. - Lennox‑Gastaut syndrome: employed as adjunct therapy to control multiple seizure types, including atonic and tonic seizures, in this severe childhood epilepsy.

Lamotrigine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: a transient feeling of light‑headedness or unsteadiness that may affect balance. - Headache: mild to moderate cranial pain that can vary in intensity and duration. - Nausea: an upset stomach sensation often accompanied by a brief urge to vomit. - Rash: mild skin erythema or itching that usually resolves without intervention.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: a severe, potentially life‑threatening skin reaction characterized by blistering, mucosal involvement, and systemic symptoms. - Toxic epidermal necrolysis: an extreme form of skin detachment affecting large body surface area, requiring urgent medical care. - Blood dyscrasias: serious hematologic abnormalities such as agranulocytosis, aplastic anemia, or pancytopenia that may present with fatigue or infection.

When using Lamotrin S, several precautionary measures should be observed to ensure safe therapy.

- Assess renal function: adjust dosing in patients with severe renal impairment. - Assess hepatic function: use caution and monitor liver enzymes in hepatic disease. - Avoid abrupt discontinuation: taper the dose to prevent seizure recurrence. - Pregnancy counseling: discuss potential risks and benefits with the prescriber before use. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lamotrin S can interact with other medicines, altering its plasma concentration or increasing toxicity.

Major Interactions (Avoid): - Valproic acid: markedly raises lamotrigine plasma levels and heightens the risk of severe cutaneous reactions such as Stevens‑Johnson syndrome. - Carbamazepine: significantly lowers lamotrigine concentrations through enzyme induction, which may diminish seizure control.

Moderate Interactions (Monitor Closely): - Oral contraceptives: estrogen‑containing pills can increase lamotrigine clearance, potentially reducing efficacy and necessitating dose review. - Rifampin: strong enzyme inducer that accelerates lamotrigine metabolism, leading to lower drug exposure. - Serotonergic agents: concurrent use may enhance central nervous system depression, requiring careful monitoring for dizziness or sedation.